TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05780190

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: New artificial liver CABA system (BS330+CA280) +PE
Description: The new artificial liver CABA system (BS330+CA280) combioned plasma exchange in the treatment of end-stage liver disease with inflammatory status

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: New artificial liver CABA system (BS330+CA280) +PE
Description: The new artificial liver CABA system (BS330+CA280) combioned plasma exchange in the treatment of end-stage liver disease with inflammatory status
Study: NCT06174220

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tideglusib
Description: Tideglusib 1g po daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo 1g po daily
Study: NCT06641921

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Seerlinq haemodynamically-guided heart failure treatment
Description: Heart failure treatment of participants in the Seerlinq intervention arm will be haemodynamically-guided based on the results from the Seerlinq telemedical monitoring system.
Study: NCT06638255

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sequence A involves administering Low PEEP for 12 hours, followed by High PEEP for 12 hours.
Description: Patients will first receive the Low PEEP protocol for 12 hours, followed by the High PEEP protocol for 12 hours. This sequence is randomized and part of a crossover trial design to assess the effects of both PEEP strategies.~Description: Patients will first receive the High or LOW PEEP protocol for 12 hours, followed by the Low or HIGH PEEP protocol for 12 hours. This sequence is randomized and part of a crossover trial design to assess the effects of both PEEP strategies.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sequence B involves setting High PEEP for 12 hours, followed by Low PEEP for 12 hours.
Description: Sequence B involves setting High PEEP for 12 hours, followed by Low PEEP for 12 hours.
Study: NCT06642740

Intervention type: OTHER
Intervention: Platelet count
Description: divide into two groups based on platelet count

Intervention type: OTHER
Intervention: Platelet count
Description: divide into two groups based on platelet count
Study: NCT04254289

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Usual care

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home-based exercise program
Description: Home-based program determined by exercise physiologist
Study: NCT06391840

Intervention type: OTHER
Intervention: Airway ultrasound
Description: Pre-operative airway ultrasound
Study: NCT04799327

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR20004
Description: SHR20004：low dose
Study: NCT05297396

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Slow Tapering of Chronic Opioid Therapy
Description: Clinically prescribed daily opioids reduced by no more than 10 morphine milligram equivalent per day (MMED) each month for 12 months
Study: NCT05824845

Intervention type: PROCEDURE
Intervention: Hip/Knee Replacement
Description: Hip/Knee Replacement
Study: NCT05671185

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Repetitive Transcranial Magnetic Stimulation
Description: rTMS using Magstim TMS system is delivered at the left dorsolateral prefrontal cortex

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Repetitive Transcranial Magnetic Stimulation
Description: rTMS using Magstim TMS system is delivered at the left dorsolateral prefrontal cortex

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Repetitive Transcranial Magnetic Stimulation
Description: rTMS using Magstim TMS system is delivered at the left dorsolateral prefrontal cortex

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Repetitive Transcranial Magnetic Stimulation
Description: rTMS using Magstim TMS system is delivered at the left dorsolateral prefrontal cortex
Study: NCT06111053

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ENDS
Description: Participants in active comparator groups that include ENDS will receive 6-weeks worth of ENDS supplies.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ENDS
Description: Participants in active comparator groups that include ENDS will receive 6-weeks worth of ENDS supplies.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CI
Description: Participants in active comparator groups will receive incentives that vary based on participant abstinence from smoking, measured by a carbon monoxide breath sample.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CI
Description: Participants in active comparator groups will receive incentives that vary based on participant abstinence from smoking, measured by a carbon monoxide breath sample.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No ENDS
Description: Participants in active comparator groups labeled No ENDS will only receive information about the comparative risk of ENDS relative to combustible cigarettes.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No ENDS
Description: Participants in active comparator groups labeled No ENDS will only receive information about the comparative risk of ENDS relative to combustible cigarettes.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NI
Description: Participants in active comparator groups labeled NI will receive compensation for each breath sample provided throughout the study, with no variation.
Study: NCT04799327

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR20004
Description: SHR20004: medium dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR20004
Description: SHR20004: high dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo
Study: NCT06111053

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NI
Description: Participants in active comparator groups labeled NI will receive compensation for each breath sample provided throughout the study, with no variation.
Study: NCT06640660

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mindlenses Professional
Description: MindLenses professional's device combines the prismatic adaptation (PA) procedure with the administration of serious games (SG) for cognitive training using a tablet

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Conventional rehabilitation
Description: Conventional rehabilition consists in computerized exercises focused on the main cognitive domains
Study: NCT06463769

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 8 week predominantly plant-based New Nordic LPF-diet program
Description: An 8-week patient-centered dietary intervention program will be implemented to maintain a predominantly plant-based New Nordic LPF-Diet.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 8 week predominantly plant-based New Nordic LPF-diet program
Description: An 8-week patient-centered dietary intervention program will be implemented to maintain a predominantly plant-based New Nordic LPF-Diet.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: maintenance of the predominantly plant-based New Nordic LPF-diet
Description: Follow-up of long-term adherence to the diet at one and six months after completion of the intervention program.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: maintenance of the predominantly plant-based New Nordic LPF-diet
Description: Follow-up of long-term adherence to the diet at one and six months after completion of the intervention program.
Study: NCT06255561

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: active rTMS stimulating
Description: Two sessions of active rTMS would be delivered, with 1800 pulse/session and 50 min inter-session intervals.
Study: NCT05193552

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hizentra
Description: subjects level of immunoglobulin replacement therapy will be adjusted for bioavailability as per manufacturer's instructions
Study: NCT04991506

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ES102
Description: The active ingredient of ES102 is a recombinant, humanized, hexavalent IgG antibody that targets the human OX40 receptor (TNFRSF4)
Study: NCT06637280

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High - flow nasal cannula
Description: High flow nasal cannula (HFNC), a device first introduced in neonates and pediatric care, is currently used in a wide range of indications in adult respiratory and critical care medicine (5-7). It is a relatively new method in bronchoscopy with several notable theoretical advantages over low flow oxygen via conventional nasal cannula (CNC):~* High flow up to 60 liters per minute ensures a more stable FiO2 and better matches the increased patient's inspiratory flow~* High flow generates a small positive expiratory airway pressure (up to 5 cm H2O) which could stabilize the upper airways during sedation and have a beneficial effect in the lower airways~* High flow reduces dead space in the upper airways and increases alveolar ventilation.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard nasal cannula
Description: Standard method for supplementing oxygen during EBUS bronchoscopy
Study: NCT04805593

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: WaveLight EX500 excimer laser system
Description: FDA approved stationary scanning-spot excimer laser system used during refractive surgery for the treatment of myopia, myopic astigmatism, hyperopia, hyperopic astigmatism, and mixed astigmatism. For this clinical study, the Wavefront Optimized (WFO) Ablation profile of the WaveLight EX500 excimer laser system will be used for bilateral LASIK treatment of hyperopia with and without astigmatism.
Study: NCT04991506

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ES102
Description: The active ingredient of ES102 is a recombinant, humanized, hexavalent IgG antibody that targets the human OX40 receptor (TNFRSF4)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JS001
Description: JS001 is administered via intravenous injection once every 21 days, every 21 days as a treatment cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JS001
Description: JS001 is administered via intravenous injection once every 21 days, every 21 days as a treatment cycle.
Study: NCT05681416

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Panel sequencing, whole exome sequencing, whole genome sequencing
Description: Besides the mutation positive men (group 2), all will receive multigene panel analysis in a patient care setting and if negative, whole exome sequencing (WES), whole genome sequencing and transcriptome analyses. In PCA-affected men (group 3), additional mutational analysis will be performed on formalin-fixed paraffin embedded (FFPE) - and fresh frozen (FF) tumor tissue from biobanked radical prostatectomy specimens using FFPE panel analysis (like TruSightOncology 500) or WES if FF samples are available.
Study: NCT05058131

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Dietary fibre
Description: Dietary fibre as a powder, 24 g per day for 6 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo compound
Description: Maltodextrin powder, 24 g per day for 6 weeks
Study: NCT05853562

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: structured vestibular rehabilitation program
Description: The structured Vestibular rehabilitation protocol consisted of a structured vestibular rehabilitation program that included vestibular adaptation exercises, oculomotor exercises, static and dynamic balance exercises, and posture exercises.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: structured vestibular rehabilitation program
Description: The structured Vestibular rehabilitation protocol consisted of a structured vestibular rehabilitation program that included vestibular adaptation exercises, oculomotor exercises, static and dynamic balance exercises, and posture exercises.
Study: NCT06635915

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Postoperative ultrasound
Description: Ultrasound will be performed to both groups in the postoperative period to assess the normoposition or the absence of nasogastric tube.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Postoperative ultrasound
Description: Ultrasound will be performed to both groups in the postoperative period to assess the normoposition or the absence of nasogastric tube.
Study: NCT05818293

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: radiofrquency device
Description: • The radiofrequency system has been used for treatment of subcutaneous fat layers.
Study: NCT05826197

Intervention type: OTHER
Intervention: Radiomics
Description: PET Radiomics
Study: NCT05255055

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical Therapy
Description: A manual therapy protocol and a therapeutic exercise protocol

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical Therapy
Description: A manual therapy protocol and a therapeutic exercise protocol
Study: NCT05425238

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood flow restriction
Description: strengthening protocol but with Blood flow restriction technique~.Standard BFR Application: a standard pressure (used for all patients) for e.g. 180~mmHg; a pressure relative to the patient's systolic blood pressure, for e.g. 1.2 - or 1.5-fold greater than systolic blood pressure.40% cuff pressure as percentage of LOP.(4) And performing BFR-RE with low load exercises. So 30% of 1 RPM would be enough 4 times a week for 6 week

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional physical therapy
Description: Resistance exercise 75 repetitions across four sets of exercises, with30 repetitions in the first set and 15 repetitions in each subsequent set. 4 times a week for 6
Study: NCT05681416

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Panel sequencing, whole exome sequencing, whole genome sequencing
Description: Besides the mutation positive men (group 2), all will receive multigene panel analysis in a patient care setting and if negative, whole exome sequencing (WES), whole genome sequencing and transcriptome analyses. In PCA-affected men (group 3), additional mutational analysis will be performed on formalin-fixed paraffin embedded (FFPE) - and fresh frozen (FF) tumor tissue from biobanked radical prostatectomy specimens using FFPE panel analysis (like TruSightOncology 500) or WES if FF samples are available.

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Panel sequencing, whole exome sequencing, whole genome sequencing
Description: Besides the mutation positive men (group 2), all will receive multigene panel analysis in a patient care setting and if negative, whole exome sequencing (WES), whole genome sequencing and transcriptome analyses. In PCA-affected men (group 3), additional mutational analysis will be performed on formalin-fixed paraffin embedded (FFPE) - and fresh frozen (FF) tumor tissue from biobanked radical prostatectomy specimens using FFPE panel analysis (like TruSightOncology 500) or WES if FF samples are available.
Study: NCT06535490

Intervention type: PROCEDURE
Intervention: EUS-FNA
Description: Puncture of pancreatic cystic lesion with a fine needle under EUS guidance

Intervention type: PROCEDURE
Intervention: EUS-FNA
Description: Puncture of pancreatic cystic lesion with a fine needle under EUS guidance

Intervention type: DRUG
Intervention: ATBp
Description: Antibiotic prophylaxis consists of a single intravenous administration before or at the beginning of the procedure according to the common practices of each practitioner or unit
Study: NCT05509088

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: high flow nasal cannula
Description: Patients in the intervention group receive oxygen through HFNC with a flow rate of set initially at 40 L / min, FiO2 adjusted to maintain SpO2 ≥ 92%, and will be humidified, heated to 34-37 °C, disconnection will be allowed only when ambulation is required, patients will be instructed to practice mouth closing throughout the HFNC therapy as much as possible
Study: NCT04805593

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: LASIK
Description: Procedure that reshapes the front part of the eye (cornea) so that light traveling through it is properly focused on the back part of the eye (retina). The procedure will be performed using the WaveLight EX500 excimer laser system.
Study: NCT06280989

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: kinesio taping
Description: Before treatment, all female participants will undergo an allergic test on the anterior surface of the elbow.~To ensure cleanliness, alcohol will be used to clean the areas to be evaluated before applying the tape. The H technique will be employed to apply KT over the lumbar region. Participants will be instructed to bend forwards from the waist, and two vertical strips will be applied. These strips will stretch the Golgi tendon organ on both sides of the spine from the top of the buttock cleft upwards to a mid-point, with less than 25% stretch .~Additionally, a horizontal strip will be attached across the left and right sacroiliac joints. This strip will be stretched to 50% of its maximum capacity,.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: myofascial release technique
Description: myofascial release technique will be applied from prone on lumbar paravertebral muscles by using the olecranon of the physical therapist for 3 minutes, thoracolumbar fascia by using cross-handed hold, with hands placed on the T12-L1 levels and on the sacrum for 5 minutes without repetition and quadratus lumborum by using elbow with low pressure obliquely towards the center of the column for 7 min.~Additionally, from supine on psoas muscle by transversal sliding of the psoas fascia. The therapist will place the hands laterally 3 cm from the umbilicus.
Study: NCT06640842

Intervention type: DIAGNOSTIC_TEST
Intervention: A combination of various test and biomarkers will be completed to understand the effect of hypertensive disorders of pregnancy in brain health in midlife.
Description: Participants will be asked to complete a blood draw, 5-lead ECG, MRI, a series of cognitive assessments, dietary assessments, monitor sleep and physical activity and DXA scan.

Intervention type: DIAGNOSTIC_TEST
Intervention: A combination of various test and biomarkers will be completed to understand the effect of hypertensive disorders of pregnancy in brain health in midlife.
Description: Participants will be asked to complete a blood draw, 5-lead ECG, MRI, a series of cognitive assessments, dietary assessments, monitor sleep and physical activity and DXA scan.
Study: NCT04828239

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: laser acupuncture
Description: 400 mW, near-infrared, continuous wavelength, 810 nm. about 24J/cm2
Study: NCT06564987

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 4% Articaine with 1:200,000 epinephrine
Description: Inferior Alveolar Nerve Block with 4% articaine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 2% lidocaine with 1:100,000 epinephrine
Description: Inferior Alveolar Nerve Block with 2% lidocaine
Study: NCT06563167

Intervention type: DIAGNOSTIC_TEST
Intervention: CXR
Description: CXRs will be performed at 3 different time points - (i) within 1 hour after TTLB, (ii) at 4 hours (± 1 hour) after TTLB and (iii) at 18 hours (± 2 hours) after TTLB.
Study: NCT06419881

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tele-drama therapy
Description: A 12-week tele-drama therapy group intervention integrating Playback Theater and Life Review Therapy

Intervention type: OTHER
Group type: OTHER
Intervention: Usual Care
Description: This arm continued to receive the routine activities provided by Uniper Care
Study: NCT05072379

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: colostomy self-care app
Description: The study will use mixed methods as the study design in which content analysis will be used to identify the content suited for the App based on interviews with participants. A systematic research and development process will be utilized to design the text, videos, and images in the App's simulations to provide accurate, consistent, and complete knowledge of the skills needed for colostomy self-care and contending with any potential emergency.
Study: NCT04853121

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Tapered Implants
Description: Tapered Implants are placed in fresh socket via dynamic navigation

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Straight Implants
Description: Straight Implants are placed in fresh socket via dynamic navigation
Study: NCT05749094

Intervention type: DIAGNOSTIC_TEST
Intervention: Optic nerve sheath ultrasound
Description: The patients are examined in a supine relaxed position. The probe is gently placed on the closed eyelid with a standard ultrasound gel and adjusted to a suitable angle to display the optic nerve entry into the eyeball. Measurements are done 3mm distal to the posterior aspect of the ocular globe. Ultrasosonographic 14L5 probe is used with a safe thermal index, mechanical index and intensity limit. All patients will also undergo a bedside fundoscopic examination. Official ophthalmology consultation will be requested in patients with visual symptoms or abnormal fundoscopy.

Intervention type: DIAGNOSTIC_TEST
Intervention: Optic nerve sheath ultrasound
Description: The patients are examined in a supine relaxed position. The probe is gently placed on the closed eyelid with a standard ultrasound gel and adjusted to a suitable angle to display the optic nerve entry into the eyeball. Measurements are done 3mm distal to the posterior aspect of the ocular globe. Ultrasosonographic 14L5 probe is used with a safe thermal index, mechanical index and intensity limit. All patients will also undergo a bedside fundoscopic examination. Official ophthalmology consultation will be requested in patients with visual symptoms or abnormal fundoscopy.

Intervention type: DIAGNOSTIC_TEST
Intervention: Standardized GCA assessment
Description: Clinical assesment, blood test review, temporal/axillary artery ultrasound

Intervention type: DIAGNOSTIC_TEST
Intervention: Standardized GCA assessment
Description: Clinical assesment, blood test review, temporal/axillary artery ultrasound
Study: NCT05848817

Intervention type: DEVICE
Intervention: Contoura LASIK
Description: Subjects receiving Phorcides Planned Contoura LASIK
Study: NCT04721106

Intervention type: DRUG
Intervention: Vizimpro
Description: treatment group
Study: NCT06043011

Intervention type: OTHER
Intervention: Routine care as per site standard.
Description: Physician's choice according to patient's needs.

Intervention type: OTHER
Intervention: Routine care as per site standard.
Description: Physician's choice according to patient's needs.

Intervention type: OTHER
Intervention: Routine care as per site standard.
Description: Physician's choice according to patient's needs.

Intervention type: OTHER
Intervention: Routine care as per site standard.
Description: Physician's choice according to patient's needs.

Intervention type: OTHER
Intervention: Routine care as per site standard.
Description: Physician's choice according to patient's needs.

Intervention type: OTHER
Intervention: Routine care as per site standard.
Description: Physician's choice according to patient's needs.